Bradley L. Campbell is the President and Chief Executive Officer and a Director of Amicus Therapeutics.

Bradley became CEO of Amicus in 2022. He joined Amicus in 2006. During his tenure with Amicus, he led the global commercialization of Galafold, the company’s first approved medicine. He also served in a range of strategic and commercial roles, including as Chief Operating Officer. Prior to Amicus, Mr. Campbell spent time in various commercial and business development roles at Genzyme and Bristol-Myers Squibb and as a strategy consultant for Marakon Associates. He brings more than 20 years of experience in the Orphan Drug industry.

Mr. Campbell currently serves on a number of Boards including the Advisory Board of the Duke Margolis Institute for Health Policy, the Biotechnology Innovation Organization, and the Corporate Advisory Board for the National Tay-Sachs and Allied Diseases Association. He previously served on the Board of Progenics Pharmaceuticals from 2016 until its successful acquisition by Lantheus Holdings in 2020, as well as ARYA Sciences Acquisition Corp III, and Gennao Bio.

He received a B.A. in Public Policy Studies from Duke University and an M.B.A. from Harvard Business School.